Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment

In this article

After years of trying to lose weight “the right way,” Jane Zuckerman realized that “putting in the work just wasn’t enough.”

Zuckerman, a 32-year-old data analyst based in Washington, D.C., said she lost 90 pounds in college and spent years cycling through nutritionists, therapy and strict routines — only to find herself at her heaviest after the pandemic, at 270 pounds.

Zuckerman said GLP-1 injections were out of the question, because she’s afraid of needles. But when the first GLP-1 pill for obesity became available in early January, Zuckerman called her doctor immediately, she said.

Almost a month after starting Novo Nordisk